KHIRON LIFE SCIENCES CORP - KHRNF STOCK NEWS

Khiron Life Sciences Corp. (TSXV: KHRN)(OTCQX: KHRNF) held its Annual General Meeting (AGM) on June 30, 2021, where shareholders approved several resolutions, including the election of a six-member Board of Directors consisting of notable figures such as Vicente Fox and Juan Carlos Echeverry. The meeting represented 34.89% of the shares.

The company has engaged Lytham Partners, LLC for investor relations services at a monthly fee of US$6,500. Lytham brings over 20 years of experience in connecting small cap companies with investors, pending approval from the TSX Venture Exchange.

Khiron Life Sciences Corp. (OTCQX: KHRNF) has achieved a significant milestone by completing its first medical cannabis sale in Brazil, tapping into a market that potentially reaches USD$1.4 billion in annual revenue. The company partnered with CANNAB to aid a child with epilepsy, marking a critical step in providing access to quality medical cannabis. Khiron aims to replicate its successful Zerenia clinic model in Brazil, enhancing patient access and education through collaborations with local pharmacies and healthcare providers. The Brazilian medical cannabis market could grow to nearly 3 million users in the coming years.

Khiron Life Sciences Corp. (OTCQX: KHRNF) plans to enter Mexico's medical cannabis market following the Supreme Court's recent decision to decriminalize adult cannabis use. This landmark ruling aligns with Khiron's strategy to leverage its experience in Colombia for a competitive edge. The company anticipates accelerating its market entry due to regulatory advancements and aims to establish clinics and educational programs in 2021. Former Mexican President Vicente Fox supports the decision, envisioning Mexico as a leading global cannabis market.

Khiron Life Sciences Corp. has announced significant advances in its entry into the Mexican medical cannabis market. On June 28, 2021, the company received a THC extract export quota from Colombia, allowing the export of up to 700 kg of medical cannabis products to Mexico. The company finalized agreements for manufacturing in Mexico and plans to launch Zerenia™ clinics nationwide by 2021. With 24,000 prescriptions already in Colombia and Peru, Khiron aims to improve the lives of 1 million patients by 2024, highlighting Mexico's importance within its expansion strategy.

Khiron Life Sciences Corp. has appointed Franziska Katterbach as the new President of Khiron Europe, succeeding Tejinder Virk, who has resigned. Katterbach, who has been with Khiron since October 2019 as Managing Director and Chief Legal Counsel, has been instrumental in expanding operations in Europe, particularly in Germany, where the company recently launched a new product and tripled shipment volumes. Virk's resignation entails forfeiting 2.2 million stock options and 600,000 restricted share units.

Khiron Life Sciences Corp. has launched its first Zerenia™ medical cannabis clinic outside of Colombia, located in Lima, Peru, through a strategic partnership with Clinica Montesur. This clinic, which serves a city of 10 million, will enhance Khiron's market reach, leveraging Clinica Montesur's infrastructure and patient base. In Q1 2021, Khiron reported a 175% increase in medical cannabis sales in Peru compared to 2020. Zerenia is a leader in Colombian cannabis sales, boasting 20,000 prescriptions and 90% average gross margins.

Khiron Life Sciences Corp. has received its largest shipment of EU-GMP certified medical cannabis to date, weighing 36.6kg. This shipment includes Khiron 20/1, a THC-dominant cannabis flower, expanding its offerings in the German market. The company anticipates a positive impact on Q2 2021 sales as Germany's medical cannabis market is projected to grow significantly, with over 100,000 patients. This product has been prescribed in the UK since July 2020. Khiron aims to enhance patient access and expand its product line in Europe.

Khiron Life Sciences Corp. (TSXV: KHRN, OTCQX: KHRNF) has announced participation in several investor events in June 2021, including the Jefferies Healthcare Conference and the Benzinga Virtual Cannabis Capital Conference. These events highlight Khiron's expansion in Latin America and Europe, backed by its recent prescription growth in Colombia, which saw over 19,000 prescriptions filled. Additionally, the company has awarded stock options and restricted share units to key executives. Khiron aims to enhance patient access and engagement in medical cannabis markets.

Khiron Life Sciences Corp. (OTCQX: KHRNF) reported record revenues of $2.8 million for Q1 2021, a 49% increase from Q1 2020. Gross profits reached $1.1 million, with a gross margin of 38%. Medical cannabis sales accounted for 20% of total revenues and contributed over 45% of gross profits. The company filled over 7,500 prescriptions in Q1 2021 and launched its first sales in Germany, with international sales making up 10% of medical cannabis revenues. As of March 31, 2021, Khiron held $12.5 million in cash.